Edgewise surges on sale of muscle dystrophy business to Servier

Edgewise Therapeutics

01/06/2026 13:57

** Shares of drug developer Edgewise Therapeutics EWTX.O rise 30.7% to $43.86 premarket
** Co says it will sell its muscle dystrophy business to French drugmaker Servier for up to $2.65 billion
** EWTX says Servier will gain access to its experimental drug sevasemten, which is being tested in Becker and Duchenne muscular dystrophy, two genetic disorders that cause progressive muscle weakness
** Co says the sale would strengthen its balance sheet and plans to use the proceeds for development of its lead candidate EDG-7500, which is being tested for the heart condition hypertrophic cardiomyopathy
** Up to last close, stock was up 37.7% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))